Sugi Predict

Sugi Predict / Targets / VKORC1L1

VKORC1L1

Vitamin K epoxide reductase complex subunit 1-like protein 1 · Q8N0U8 · VKORC1L1 on Sugi Atlas →

0 patent compounds predicted against VKORC1L1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to VKORC1L1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care PHASE4WITHDRAWN
Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy PHASE4COMPLETED
EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon PHASE4COMPLETED
EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol PHASE4COMPLETED
EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin PHASE4COMPLETED
The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement. PHASE4UNKNOWN
Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose PHASE3UNKNOWN
Does Low Dose Oral Vitamin K Improve International Normalized Ratio (INR) Stability? PHASE3COMPLETED
Protocol for Improvement of Therapy With Warfarin PHASE3ENROLLING_BY_INVITATION
Low Dose Supplementation to Improve Anticoagulation Control With Oral Vitamin K as an Adjuvant to Warfarin Therapy PHASE3COMPLETED
Drug Interaction Study of Warfarin and MT-3995 PHASE1COMPLETED
Human Cytochrome P450 4F Enzymes and Drug Interactions PHASE1COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings nanCOMPLETED
VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management nanUNKNOWN
Pharmacogenetics of Acenocoumarol nanCOMPLETED
The Study of Warfarin Maintenance Dose in Chinese Patients nanUNKNOWN
The Prevalence of Sub Optimal Anti Coagulation nanUNKNOWN
Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information nanCOMPLETED
Genotype-Guided Warfarin Therapy Trial nanCOMPLETED
Genetic Response to Warfarin in Healthy Subjects nanCOMPLETED
Warfarin Effects on Male Fertility After Cardiac Surgery nanNOT_YET_RECRUITING
Safer Warfarin Treatment nanSUSPENDED
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics nanCOMPLETED
Evaluating LumiraDx INR Test Accuracy in Patients Taking Phenprocoumon Anticoagulant. nanCOMPLETED
Aortic Calcification and Vitamin K Antagonists nanCOMPLETED
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR nanUNKNOWN
Genetic Determinants of Warfarin Anticoagulation Effect nanUNKNOWN
Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin) nanCOMPLETED
Evaluation of Primex's PGX Assay to Assess the Clinical Utility of Pharmacogenomics nanUNKNOWN
Pharmacogenetic Dosage Algorithm for Acenocoumarol nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a VKORC1L1 binder may also engage these)

ProteinNameSimilarity
Q6TEK5 — 1.000 Q6TEK5 →
Q6TEK3 — 0.998 Q6TEK3 →
Q6TEK4 — 0.997 Q6TEK4 →
VKORC1 Vitamin K epoxide reductase complex subunit 1 0.996 landscape →
Q6TEK8 — 0.994 Q6TEK8 →
Q6B4J2 — 0.990 Q6B4J2 →
Q9CRC0 — 0.989 Q9CRC0 →
A2XX57 — 0.976 A2XX57 →
Q6DGF8 — 0.975 Q6DGF8 →
Q8BI36 — 0.975 Q8BI36 →
Q9D6H5 — 0.973 Q9D6H5 →
Q5U4Q2 — 0.973 Q5U4Q2 →
Q02739 — 0.973 Q02739 →
P36380 — 0.973 P36380 →
Q6PEY0 — 0.972 Q6PEY0 →
Q2KIB3 — 0.972 Q2KIB3 →
D4AD75 — 0.972 D4AD75 →
Q9VXD6 — 0.972 Q9VXD6 →
Q9JYC6 — 0.972 Q9JYC6 →
Q7T047 — 0.972 Q7T047 →
Q9UTD3 — 0.972 Q9UTD3 →
Q9NTQ9 — 0.971 Q9NTQ9 →
Q753C1 — 0.971 Q753C1 →
P28231 — 0.971 P28231 →
A1Z7R6 — 0.971 A1Z7R6 →
F1QYC4 — 0.971 F1QYC4 →
Q5CZ37 — 0.971 Q5CZ37 →
Q39II6 — 0.971 Q39II6 →
Q96B42 — 0.971 Q96B42 →
Q7M734 — 0.971 Q7M734 →